Integra LifeSciences, AlloSource sign agreement for acellular dermal matrices: 4 takeaways

Integra LifeSciences entered into an agreement with AlloSource.

Advertisement

Here are four takeaways:

 

1. AlloSource is a provider of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care.

 

2. Under the agreement, Integra gains access to acellular dermal matrices derived from donated human dermis along with rights to market these matrices.

 

3. In particular, Integra’s new product line, marketed under the name HuMend Acellular Dermal Matrix, will allow Integra to offer soft tissue repair solutions for patients undergoing plastic reconstructive procedures.

 

4. Integra expects to launch HuMend in mid-2016.

 

More articles on devices:
Lattice Biologics to launch three MAR products — 3 highlights
Bone Biologics completes $5M+ financing round: 3 things to know
RTI Surgical launches laminoplasty fixation system: 4 key notes

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new technology acquisitions to regulatory clearances to leadership changes, here are 20 developments and updates from the biggest players…

  • SurGenTec’s ION-C earned FDA 510(k) clearance for ION-C navigation instruments with the ION-C posterior cervical facet fixation implant, according to…

  • VB Spine has made big pushes into the spine medtech space so far in 2026, including global expansions. Six headlines…

Advertisement

Comments are closed.